460 likes | 601 Views
Ranibizumab and bevacizumab for neovascular armd * The CATT research group*. Juan G. Santiago, MD Valley Retina Institute, P.A. May 6, 2011. Background. In 2005, clinical trials have established the efficacy of ranibizumab ( Lucentis ) for the treatment of neovascular AMD.
E N D
Ranibizumab and bevacizumab for neovasculararmd*The CATT research group* Juan G. Santiago, MD Valley Retina Institute, P.A. May 6, 2011
Background • In 2005, clinical trials have established the efficacy of ranibizumab (Lucentis) for the treatment of neovascular AMD. • Ophthalmologists began treating neovascular AMD with off-label bevacizumab (Avastin). • Bevacizumab is the most commonly used drug in the US for neovascular AMD, despite the absence of large scale clinical trial data supporting its use
Background • As needed regimen has been adopted widely for Lucentis, instead of the monthly regimen used in the pivotal trials. • Comparison of Age Related Macular Degeneration Treatment Trials (CATT) • Assess the relative efficacy and safety of Lucentis and Avastin • Determine whether as needed treatment compromise visual acuity, as compared to monthly treatment.
Methods • 1185 patients at 43 clinical centers in the US • Eligibility criteria • 50 years or more • Untreated active CNV due to AMD • Leakage on FA • Fluid on OCT • Within or below retina • Below RPE • Hemorrhage under fovea • VA between 20/25 and 20/320
As-Needed Groups • Treatment if signs of active neovascularization • Fluid on OCT • New or persistent hemorrhage • Decreased VA compared to previous exam • Dye leakage or increased lesion size on FA
Outcomes • Primary • Mean change in VA between baseline and 1 year • Secondary • Patients with a VA change of ≥ 15 letters • Number of injections • Change in fluid and foveal thickness on OCT • Change in lesion size on FA • Incidence of ocular and systemic adverse events • Annual drug cost
Findings on OCT • Results for a typical study patient at baseline, with a marked increase in retinal thickness caused by IR fluid, SR fluid, and sub-RPE fluid
Findings on OCT • Small area of IR fluid, approximately equal to the median amount of fluid that was present in patients assigned to treatment as needed who did not receive treatment even though the reading-center graders identified fluid. • Lucentis as needed - 26.5% • Avastin as needed - 23.4%
Findings on OCT • Retinal thickness at 12 months in a patient treated with ranibizumab monthly
Findings on OCT • 12-month results for a patient who was treated with bevacizumab monthly
Mean change in total retinal thickness at the fovea during the first year of follow-up
Adverse Events Rates of death, MI, stroke were similar for either drug Serious AE were higher in Avastin (24.1%) vsLucentis (19.0%)
Conclusions • Lucentis and Avastin, had equivalent effects on VA when administered according to the same schedule. • VA results could be achieve with less than monthly treatments. • Both reduce amount of fluid in or under the retina, but Lucentis patients showed a greater proportion of complete resolution of fluid. • Differences in rates of serious AE require further study.
Impressions • Equivalent but no identicals. • Lucentis data appeared better in places. • No data to suggest that patients receiving Avastin need to be switch to Lucentis or viceversa. • Costs • Lucentis $2000/dose • Avastin $50/dose
Impressions • Avastin with slightly higher risk of SAE? • Not clinically significant • Two year results may give further light on SAE differences • If concerned about SAE, Macugen is an option! • Monthly vs as-needed treatments • Compliance of office visits every 4 weeks • What about treat and extend? • Communication between physician and patient.